LONDON AstraZeneca's immunotherapy drug Imfinzi has won crucial approval from U.S. regulators for use in lung cancer, opening up a multibillion-dollar market for a medicine that has so far lagged behind competitors.
(Reuters Health) - Babies who are born much too soon or who arrive weighing too little may not score as high on intelligence tests during childhood as full-term infants, a research review suggests.
(Reuters Health) - In the first year after being told by a doctor that they have acne, patients’ risk for a diagnosis of major depressive disorder spikes by more than 60 percent compared to the general population, a new study shows.
Switzerland's Novartis AG is preparing to auction its U.S. generic pill business, looking to shed a unit that has struggled amid fierce price competition, people familiar with the matter said on Friday.
(Reuters Health) - A shortage of clinicians specializing in pediatric behavioral and developmental disorders is translating into long wait times for new patient appointments amid surging demand, a new study suggests.